PCN59 Health Utility Values in Small Cell Lung Cancer: A Literature Review

Abstract

Listen

Translate article

Small cell lung cancer (SCLC) constitutes substantial disease burden with significant negative impact on survival and quality-of-life. Health state utilities are essential in economic evaluation and vary significantly across the countries. Given the scarce data on health utility score (HUS) for SCLC, the current literature review assessed the utility values in SCLC. An extensive literature search was conducted on EMBASE, MEDLINE (via-Ovid), and Cochrane Library by combination of Emtree/MeSH terms and keywords from inception to 07-January-2021. Bibliography of included studies and web searches were also conducted for additional publications. Studies investigating the HUS in SCLC were included. The quality assessment was performed by Cochrane-risk-of-bias tool and Newcastle-Ottawa-Scale. 10 studies were included after a comprehensive review of 527 citations. Majority of the studies used EQ-5D to estimate the HUS. The HUS at the start of first-line (1L), and second-line was 0.70 and at third-line 0.76 for patients with extensive disease SCLC (ED-SCLC) receiving care in US community oncology centers. HUS was higher (indicates better health state) for ED-SCLC patients on chemotherapy with stable disease (0.72 vs. 0.69 vs. 0.76) compared with progressive disease (0.52 vs. 0.37 vs. 0.53) for Canada, UK, and US, respectively. In Taiwan, HUS was higher in limited stage SCLC patients (0.87) than ED-SCLC (0.84) in younger (<65-years) but no difference in older (≥65-years) patients with limited (0.84) and extensive stage SCLC (0.84). HUS for ED-SCLC patients receiving 1L Atezolizumab+Carboplatin+Etoposide were higher than Carboplatin+Etoposide alone and the estimates were 0.736 vs. 0.723, 0.770 vs. 0.757, 0.730 vs. 0.725, 0.755 vs 0.750, 0.748 vs. 0.739 and 0.762 vs. 0.756 for Australia, Canada, France, Netherlands, UK and USA, respectively. Progressive ED-SCLC patients had worse HUS than patients with stable ED-SCLC. This literature review provides the health utility data to perform economic evaluation for Health Technology Assessment for SCLC.